Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00465803 · ClinicalTrials.gov registry record · Phase 3
A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension
A Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT00465803 is a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma that has completed, run by Alcon Research. The registered enrollment target is 81 participants, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00465803, a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess patient compliance with DuoTrav versus concomitant administration of Timolol 0.5% plus TRAVATAN in patients with open-angle glaucoma or ocular hypertension.
Conditions Studied
Interventions
- DRUG Travoprost 0.004%/timolol 0.5% ophthalmic solution
- DRUG Travoprost ophthalmic solution, 0.004%
- DRUG Timolol maleate ophthalmic solution, 0.5%
Study Locations (1)
Washington
- Seattle - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00465803
The ClinicalTrials.gov registry entry for NCT00465803 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (71% lower). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Travoprost 0.004%/timolol 0.5% ophthalmic solution is the first listed.
NCT00465803 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00465803 about?
NCT00465803 is a clinical study titled "A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension". The purpose of this study is to assess patient compliance with DuoTrav versus concomitant administration of Timolol 0.5% plus TRAVATAN in patients with open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT00465803?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 81 participants. The study started on 2007-03.
What conditions does trial NCT00465803 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT00465803?
The interventions under investigation include: Travoprost 0.004%/timolol 0.5% ophthalmic solution (DRUG), Travoprost ophthalmic solution, 0.004% (DRUG), Timolol maleate ophthalmic solution, 0.5% (DRUG).
Who is sponsoring clinical trial NCT00465803?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00465803 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.